Safety Study of OXi4503 (a Vascular Disrupting Agent) Given by 3 x Weekly Intravenous Infusions to Patients With Advanced Solid Tumors

- Histologically proven cancer.

- Written informed consent.

- Age >/= 18 years.

- Life expectancy of at least 12 weeks.

- World Health Organization (WHO) performance status of 0 or 1.

- Adequate Hematological and biochemical indices to support investigational therapy.

- All women of childbearing potential (WOCBP) must have a negative serum pregnancy test.

- WOCBP and fertile men and their partners must agree to use an effective form of contraception during the study and for 90 days after the last dose of study medication.

- Measurable and evaluable disease.

- All toxic manifestations of previous treatment must have resolved.

- Able to undergo MRI scanning.

- Radiotherapy, endocrine therapy, immunotherapy or chemotherapy during the previous four weeks (six weeks for nitrosureas and Mitomycin-C) prior to treatment.

- Pregnant and lactating women.

- Major thoracic and/or abdominal surgery in the preceding four weeks from which the patient has not yet recovered.

- Patients which have active uncontrolled infections.

- Patients with any other condition that in the Investigator's opinion would not make the patient a good candidate for the clinical trial.

- Patients known to be serologically positive for Hepatitis B, Hepatitis C or Human Immunodeficiency Virus (HIV).

- Previous or ongoing cardiac conditions.

- Uncontrolled hypertension.

- Patients taking any drug known to prolong the QTc interval.

- Patients who have had any ischaemic or vascular damage from previous radiotherapy.

- Patients taking warfarin or heparin.

- Patients taking naproxen.

- Patients taking supplements or multivitamins containing vitamin C.

- Patients should not be taking any other investigational drug for the duration of the study.

- Patients with brain metastases or neurological tissue involvement of the spinal column.